Bard Surgery, Vascular Offerings Lead Q1 Growth; Margins Help Boost R&D
This article was originally published in The Gray Sheet
Executive Summary
FDA has indicated that Bard's anti-infection endotracheal tube will be regulated as a device/drug combination product, the firm says
You may also be interested in...
Bard Vascular Unit To Do Heavy Lifting As Hernia Sales Growth Slows
Bard is reevaluating its programmable pain pump strategy due to developmental delays caused by imaging technology compatibility issues
Bard Vascular Unit To Do Heavy Lifting As Hernia Sales Growth Slows
Bard is reevaluating its programmable pain pump strategy due to developmental delays caused by imaging technology compatibility issues
Bard clarification
Firm's anti-infection endotracheal tube is coated with a new formulation of silver hydrogel anti-microbial technology internally developed by Bard and specifically formulated to address ventilator-associated pneumonia. The device does not use BactiGuard technology, as previously reported (1"The Gray Sheet" April 21, 2003, p. 21)...